Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K Current Report is filed by Healthcare Trust, Inc. (not National Healthcare Properties, Inc.) for the reporting period of October 1, 2021. The filing details the entry into a material definitive agreement for an underwritten public offering of preferred stock and related amendments to the company's operating partnership agreement and articles of incorporation.

Key Financial Metrics and Capital Structure

  • Offering Size: 3,200,000 shares of 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock.
  • Offering Price: $25.00 per share.
  • Expected Net Proceeds: Approximately $77.5 million (after underwriting discount, excluding other estimated offering expenses).
  • Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 480,000 shares.
  • Dividend Rate: 7.125% per annum ($1.78125 per share).
  • Liquidation Preference: $25.00 per share.
  • Seniority: Ranks on parity with the 7.375% Series A Preferred Stock and senior to Common Stock.

Material Changes and Use of Proceeds

The primary material change is the authorization and issuance of the Series B Preferred Stock. The net proceeds from the offering are designated for the following uses:

  1. Repayment of amounts outstanding under the company's revolving credit facility as required by the facility terms.
  2. General corporate purposes, including the purchase of additional properties, if the revolving credit facility is fully repaid.
  3. The company may subsequently re-borrow amounts repaid to the credit facility for general corporate purposes.

Outlook, Risks, and Unusual Items

Redemption Terms: The Series B Preferred Stock is redeemable at the company's option on or after October 6, 2026, at $25.00 per share plus accrued dividends. Early redemption is permitted upon a Delisting Event or Change of Control.

Delisting Event Penalty: If a Delisting Event occurs, the dividend rate increases by 2.00% per annum to 9.125% ($2.28125 per share) until the event is cured.

Voting Rights: Holders generally have no voting rights unless six or more quarterly dividends are in arrears, at which point they may elect two additional directors.

Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to risk factors outlined in the company's 2020 Form 10-K.

Investor Verification Checklist

  • Verify the final closing date of the offering (scheduled for October 6, 2021) and the actual net proceeds received.
  • Confirm the extent to which proceeds were used to repay the revolving credit facility versus general corporate purposes.
  • Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification liabilities and underwriting discounts.
  • Monitor the company's ability to maintain listing status to avoid the 9.125% dividend penalty rate.
  • Check subsequent filings for the exercise of the 480,000 share over-allotment option.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.